Announcement of Shanghai Miracle Pharmaceutical Investment Management Co., Ltd. on the 2025 profit distribution plan and the request to the shareholders’ meeting to authorize the board of directors to formulate the 2026 interim dividend plan
Securities code: A shares 600613 Stock abbreviation: A shares Miracle Pharmaceuticals Number: 2026-008 B shares 900904 B shares Miracle B shares
Shanghai Miracle Pharmaceutical Investment Management Co., Ltd.
Announcement on the 2025 profit distribution plan and the request to the shareholders’ meeting to authorize the board of directors to formulate the 2026 interim dividend plan
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and bear individual and joint liability for the authenticity, accuracy and completeness of its contents.
Important content reminder:
Distribution ratio: Cash dividend of RMB 0.70 (tax included) for every 10 shares.
This profit distribution is based on the total share capital registered on the equity registration date of the equity distribution. The specific date will be specified in the equity distribution implementation announcement.
If the company's total share capital changes before the equity registration date for equity distribution, it is planned to maintain the distribution ratio per share unchanged, adjust the total distribution amount accordingly, and will disclose it in relevant announcements.
This profit distribution plan still needs to be submitted to the company’s shareholders’ meeting for review and approval before it can be implemented.
1. Contents of profit distribution plan
As audited by Lixin Accounting Firm (Special General Partnership), Shanghai Miracle Pharmaceutical Investment Management Co., Ltd. (hereinafter referred to as the "Company") achieved a net profit attributable to shareholders of the listed company of RMB 38,245,006.63 in its 2025 consolidated financial statements. As of December 31, 2025, the undistributed profit of the company's parent company at the end of the reporting period was RMB 117,710,149.16. In accordance with the relevant provisions of the "Cash Dividend Distribution Guidelines for Listed Companies of the Shanghai Stock Exchange" and the "Articles of Association" and taking into account the actual situation of the company, the company's board of directors has formulated an annual profit distribution plan for 2025. The details are as follows:
The company plans to distribute a cash dividend of 0.70 yuan (tax included) to all shareholders for every 10 shares based on the total share capital of 534,071,628 shares on December 31, 2025. A total of 37,385,013.96 yuan in cash dividends will be distributed, accounting for 2025 In the year, 97.75% of the net profit attributable to shareholders of the listed company was realized; the accumulated undistributed profits were carried forward to be distributed in subsequent years.
If the company’s total share capital changes between the date of this announcement and the equity registration date for the implementation of equity distribution,
The company plans to maintain the distribution ratio unchanged, adjust the total distribution amount accordingly, and will separately announce the specific adjustments;
- No capital reserve will be converted into share capital.
This profit distribution plan still needs to be submitted to the company's shareholders' meeting for review.
2. Cash dividends in the last three fiscal years
Project 2025 2024 Total cash dividends in 2023 (yuan) 37,385,013.96 80,110,744.20 53,407,162.80 Total repurchase and cancellation (yuan) —
Net profit attributable to shareholders of listed companies
38,245,006.63 71,388,047.35 57,000,674.55 (yuan)
The parent company's undistributed profits at the end of the year
117,710,149.16 yuan (yuan)
Cumulative cash points for the past three fiscal years
170,902,920.96 total bonus (yuan)
Cumulative cash points for the past three fiscal years
No
Whether the total amount of bonus is less than 50 million yuan
Cumulative repurchase notes in the past three fiscal years
—
Total sales (yuan)
Average net profit for the past three fiscal years
55,544,576.18 (yuan)
Cumulative cash points for the past three fiscal years
170,902,920.96 Total red and repurchase cancellation (yuan)
Cash dividend ratio (%) 307.69 Is the cash dividend ratio less than 30%? No
Whether it touches Article 1 of the Stock Listing Rules?
Article 9.8.1 Paragraph 1 (8)
No
Certain other risk warnings may be implemented
situation
As shown in the table above, the company’s cumulative cash dividends in the past three fiscal years are higher than those in the past three fiscal years.
30% of the average annual net profit for the year, and does not violate the provisions of Article 9.8.1, Paragraph 1 (8) of the "Stock Listing Rules"
Certain situations may result in other risk warnings being implemented.
3. Request the shareholders’ meeting to authorize the board of directors to formulate an interim profit distribution plan for 2026
(1) Specific conditions for the company’s mid-term (half-year or third quarter) dividend distribution in 2026:
Profitable during the reporting period and the undistributed profits in the parent company’s statements are positive;
The company’s cash flow can meet the needs of normal operations and sustainable development;
Comply with the requirements for profit distribution of listed companies in the "Supervisory Guidelines for Listed Companies No. 3 - Cash Dividends of Listed Companies", "Stock Listing Rules of the Shanghai Stock Exchange", "Articles of Association" and other relevant regulations.
(2) The upper limit of the amount of interim dividends:
The amount of the company's interim dividend in 2026 shall not exceed the net profit attributable to the company's shareholders for the current period.
(3) Arrangement and authorization of interim dividend distribution in 2026
The 2026 mid-term profit distribution plan needs to be combined with the company's 2026 mid-term operating conditions, profitability levels, future development plans, capital needs, investor returns and other factors, and formulate a scientific and reasonable mid-term dividend plan under the conditions of profit distribution. The shareholders' meeting is requested to authorize the board of directors to formulate a specific mid-term dividend plan for 2026 subject to the conditions of profit distribution.
4. Decision-making procedures implemented by the company
- Convening, deliberation and voting of board of directors meetings
On April 27, 2026, the 13th meeting of the company's 11th board of directors reviewed and approved the "Company's 2025 Profit Distribution Plan and the Proposal to Request the Shareholders Meeting to Authorize the Board of Directors to Formulate the 2026 Interim Dividend Plan" and agreed to submit the proposal to the company's shareholders' meeting for review.
- Opinions of the Audit Committee
On April 17, 2026, the second meeting of the Audit Committee of the company's board of directors in 2026 reviewed and approved the "Company's 2025 Profit Distribution Plan and the Proposal to Submit to the General Meeting of Shareholders to Authorize the Board of Directors to Formulate the 2026 Interim Dividend Plan." The Audit Committee believes that the company's 2025 profit distribution plan and the 2026 interim dividend authorization are in line with the company's current actual situation and the relevant provisions of the Company Law and the Articles of Association, and there is no harm to the interests of the company's shareholders, especially small and medium-sized shareholders.
3. Related risk warnings
This profit distribution plan and the proposal to the shareholders' meeting to authorize the board of directors to formulate the 2026 interim dividend plan must be reviewed and approved by the company's shareholders' meeting before implementation. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Shanghai Miracle Pharmaceutical Investment Management Co., Ltd.
April 29, 2026